Overview

An Open Label SLV308 Safety Extension to Study S308.3.002 in Patients With Parkinson's Disease Experiencing Motor Fluctuations.

Status:
Completed
Trial end date:
2009-05-01
Target enrollment:
Participant gender:
Summary
This study is a multicenter, 9 months, open label extension study for all patients who are willing and eligible to continue from the pivotal, double-blind S308.3.002 study.
Phase:
Phase 3
Details
Lead Sponsor:
Solvay Pharmaceuticals